This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MARUNCIC, M. Articles by CASPER, R. F. Search for Related Content PubMed PubMed Citation Articles by MARUNCIC, M. Articles by CASPER, R. F.

The Effect of Luteal Phase Estrogen Antagonism on Luteinizing Hormone Pulsatility and Luteal Function in Women^*

MRC Group in Reproductive Biology and the Departments of Obstetrics and Gynecobgy and Physiology, University of Western Ontario London, Canada N6A 5A5

Address all correspondence and requests for reprints to: Dr. R. F. Casper, Department of Gynecology, University Hospital, 339 Winder-mere Road, London, Ontario, Canada N6A 5A5.

Pulsatile LH secretion was studied to determine if the frequency of LH pulses was altered by the administration of clomiphene citrate (CC; 150 mg) for 5 days during the midluteal phase of the menstrual cycle. Seven normal women received CC or placebo in alternate cycles in a randomized double blind fashion. On the day after drug administration, blood samples were obtained at 15-min intervals for 8 h for serum LH determinations. Daily blood samples were also obtained throughout the luteal phase for determination of serum LH, estradiol (E2), and progesterone. LH pulse frequency increased from 2.4 ± 0.5 (±SEM)/8 h after placebo to 3.9 ± 0.6/8 h (P < 0.01) after CC treatment, but pulse amplitude did not change. The transverse mean of serum LH was higher after CC (13.6 ± 0.5 mlU/ml) than after placebo (8.4 ± 0.3 mlU/ml; P < 0.001), and luteal phase length was increased from 13.5 ± 0.5 to 16.0 ± 0.4 days (P < 0.001) by administration of CC. Luteal phase levels of E2 and progesterone measured daily were significantly elevated (P < 0.01) in CC-treated cycles. These findings suggest that CC increases the frequency of hypothalamic GnRH secretory episodes, perhaps by an action involving a decrease in endogenous opioid peptide activity. Since peripheral progesterone levels were elevated in the CC-treated cycles, E2 may play a permissive role in the ability of progesterone to increase endogenous opioid peptide activity acutely. Furthermore, since the luteal phase was significantly prolonged by an increase in endogenous LH pulse frequency, the slow frequency of LH pulses in the normal late luteal phase may contribute to the onset of luteolysis in the human.

^* This work was supported by a grant from the MRC of Canada and the University Hospital Research Fund.

Received May 28, 1986.

This article has been cited by other articles:

				N. G M Beckers, P. Platteau, M. J Eijkemans, N. S Macklon, F. H de Jong, P. Devroey, and B. C J M Fauser The early luteal phase administration of estrogen and progesterone does not induce premature luteolysis in normo-ovulatory women. Eur. J. Endocrinol., August 1, 2006; 155(2): 355 - 363. [Abstract] [Full Text] [PDF]

				H. M. Fraser, H. Wilson, K. D. Morris, I. Swanston, and S. J. Wiegand Vascular Endothelial Growth Factor Trap Suppresses Ovarian Function at All Stages of the Luteal Phase in the Macaque J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5811 - 5818. [Abstract] [Full Text] [PDF]

				C. R. McCartney, M. B. Gingrich, Y. Hu, W. S. Evans, and J. C. Marshall Hypothalamic Regulation of Cyclic Ovulation: Evidence That the Increase in Gonadotropin-Releasing Hormone Pulse Frequency during the Follicular Phase Reflects the Gradual Loss of the Restraining Effects of Progesterone J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2194 - 2200. [Abstract] [Full Text] [PDF]